Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

被引:1
|
作者
Satirer, Oezlem [1 ,2 ]
Henes, Joerg C. [3 ,4 ]
Doering, Michaela [5 ]
Lesk, Till [6 ]
Benseler, Susanne [7 ,8 ]
Kuemmerle-Deschner, Jasmin Beate [1 ,2 ]
机构
[1] Univ Klinikum Tubingen, Dept Paediat, Tubingen, Baden Wurttembe, Germany
[2] Univ Klinikum Tubingen, Autoinflammat Reference Ctr Tuebingen arcT, Tubingen, Baden Wurttembe, Germany
[3] Univ Klinikum Tubingen, Ctr Interdisciplinary Clin Immunol Rheumatol & Aut, Tubingen, Baden Wurttembe, Germany
[4] Univ Klinikum Tubingen, Dept Internal Med Oncol Haematol Immunol & Rheumat, Tubingen, Baden Wurttembe, Germany
[5] Univ Tubingen, Pediat Hematol & Oncol, Tubingen, Baden Wurttembe, Germany
[6] Univ Klinikum Tubingen, Tubingen, Baden Wurttembe, Germany
[7] Alberta Childrens Hosp Res Inst, Rheumatol, Calgary, AB, Canada
[8] Childrens Hlth Ireland, Dublin, Ireland
来源
RMD OPEN | 2024年 / 10卷 / 03期
关键词
Treatment; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; JUVENILE IDIOPATHIC ARTHRITIS; CAR T-CELLS; SYSTEMIC-SCLEROSIS; ACTIVITY CRITERIA; INTERNATIONAL CONSENSUS; ETANERCEPT; GUIDELINES; BLOOD; IMMUNOTHERAPY; MULTICENTER;
D O I
10.1136/rmdopen-2024-004381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7-19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves' disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Prospects of Stem Cell Transplantation in Autoimmune Diseases
    Richard A. Nash
    Journal of Clinical Immunology, 2000, 20 : 38 - 45
  • [22] Cellular therapy for autoimmune diseases: Beyond autologous hematopoietic stem cell transplantation
    Maria, A. T. J.
    REVUE DE MEDECINE INTERNE, 2023, 44 : A35 - A40
  • [23] Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report
    Sossa Melo, Claudia Lucia
    Maria Pena, Angela
    Antonio Salazar, Luis
    Ines Jimenez, Sara
    David Gomez, Edgar
    Marcela Chalela, Claudia
    Ayala-Castillo, Miguel
    Mauricio Pena, Ivan
    NEUROMUSCULAR DISORDERS, 2019, 29 (02) : 142 - 145
  • [24] Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort
    Carlos Jaime-Perez, Jose
    Gonzalez-Trevino, Mariana
    Melendez-Flores, Jesus D.
    Ramos-Davila, Eugenia M.
    Cantu-Rodriguez, Olga G.
    Gutierrez-Aguirre, Cesar H.
    Galarza-Delgado, Dionicio A.
    Gomez-Almaguer, David
    CLINICAL RHEUMATOLOGY, 2022, 41 (03) : 869 - 876
  • [25] Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how
    Szczechowski, Lech
    Smilowski, Marek
    Helbig, Grzegorz
    Krawczyk-Kulis, Malgorzata
    Kyrcz-Krzemien, Slawomira
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (10) : 867 - 871
  • [26] Stem cell transplantation for autoimmune diseases
    John Moore
    P. Brooks
    Springer Seminars in Immunopathology, 2001, 23 : 193 - 213
  • [27] Editorial: Immune Profile After Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: Where Do We Stand?
    Ribeiro Malmegrim, Kelen Cristina
    Toubert, Antoine
    Farge, Dominique
    Oliveira, Maria Carolina
    FRONTIERS IN IMMUNOLOGY, 2020, 10
  • [28] Stem cell transplantation in autoimmune diseases
    Florea, L.
    Farge, D.
    REVUE DE MEDECINE INTERNE, 2008, 29 (02): : 80 - 83
  • [29] Autologous Hematopoietic Stem Cell Transplantation for Childhood Autoimmune Disease
    Milanetti, Francesca
    Abinun, Mario
    Voltarelli, Julio C.
    Burt, Richard K.
    PEDIATRIC CLINICS OF NORTH AMERICA, 2010, 57 (01) : 239 - +
  • [30] Virtual learning object in hematopoietic stem cell transplantation for autoimmune diseases
    Zombrilli, Andreia Ferreira
    Leopoldo, Vanessa Cristina
    Oliveira, Maria Carolina
    Cirioli de Oliveira, Marilia de Fatima
    Dolci, Mariana Ehmke
    Merizio Martins Braga, Fernanda Titareli
    de Campos Pereira Silveira, Renata Cristina
    REVISTA BRASILEIRA DE ENFERMAGEM, 2019, 72 (04) : 994 - 1000